Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL D TRUONG

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1992720916
CMS profile
44605
Location
FOUNTAIN VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$29,244.06

279 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 5 of 6; records 201–250 of 279 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL D TRUONG

NPI 1992720916 · CMS profile ID 44605

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

FOUNTAIN VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 279 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992720916?year=2022&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL D TRUONG, NPI 1992720916, CMS profile ID 44605. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 279 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992720916?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DANIEL D TRUONG, NPI 1992720916, CMS profile ID 44605. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 279 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992720916?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DANIEL D TRUONG, NPI 1992720916, CMS profile ID 44605, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 279 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1992720916?year=2022&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

279 matching records · $29,244.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 279 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 279.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $20.5804/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892554163 CMS
Avion Pharmaceuticals $17.1104/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926515153 CMS
Novartis Pharmaceuticals Corporation $13.7804/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894424323 CMS
AstraZeneca Pharmaceuticals LP $13.8704/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915800393 CMS
EISAI INC. $22.7404/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908028829 CMS
Kyowa Kirin, Inc. $19.0104/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905042391 CMS
Biogen, Inc. $25.5704/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923454777 CMS
Biohaven Pharmaceutical Holding Company Ltd. $19.6504/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923757581 CMS
Biogen, Inc. $18.3404/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923411917 CMS
Ipsen Biopharmaceuticals, Inc $18.7404/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893390443 CMS
Banner Life Sciences, LLC $13.5904/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957718645 CMS
Novartis Pharmaceuticals Corporation $3.5004/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894424321 CMS
Merz Pharmaceuticals, LLC $19.2204/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943789317 CMS
UCB, Inc. $16.5104/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908003807 CMS
Amgen Inc. $16.9604/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939400495 CMS
Amneal Pharmaceuticals LLC $20.4203/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956605623 CMS
Biohaven Pharmaceutical Holding Company Ltd. $19.4803/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923757579 CMS
CSL Behring $25.0303/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940938095 CMS
Sunovion Pharmaceuticals Inc. $20.5503/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920982855 CMS
Acorda Therapeutics, Inc $7.4503/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920333149 CMS
Allergan, Inc. $18.2803/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889999037 CMS
SK Life Science, Inc. $19.4403/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940709369 CMS
Kyowa Kirin, Inc. $18.6303/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905042387 CMS
Biohaven Pharmaceutical Holding Company Ltd. $5.5203/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923757577 CMS
GENZYME CORPORATION $23.3503/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938776621 CMS
Novartis Pharmaceuticals Corporation $14.1603/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894424313 CMS
Amgen Inc. $16.6703/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939400493 CMS
MDD US Operations, LLC $21.8103/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951620511 CMS
Novartis Pharmaceuticals Corporation $14.8803/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894424319 CMS
Biogen, Inc. $26.3803/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923453457 CMS
Acorda Therapeutics, Inc $16.5103/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920333147 CMS
Ipsen Biopharmaceuticals, Inc $19.3203/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893389289 CMS
Avion Pharmaceuticals $22.3603/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926515147 CMS
EISAI INC. $21.3003/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908028821 CMS
ABBVIE INC. $18.6903/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892554161 CMS
Abbott Laboratories $13.1203/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920588141 CMS
SK Life Science, Inc. $17.3002/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940709365 CMS
Biogen, Inc. $20.6402/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923389265 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.7802/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955857785 CMS
Allergan, Inc. $16.7302/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889999035 CMS
Amneal Pharmaceuticals LLC $1,946.0002/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956605617 CMS
Biohaven Pharmaceutical Holding Company Ltd. $19.3902/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923757575 CMS
Novartis Pharmaceuticals Corporation $5.6802/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894424317 CMS
Amneal Pharmaceuticals LLC $20.6802/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956605613 CMS
Banner Life Sciences, LLC $15.1502/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957717695 CMS
Avion Pharmaceuticals $11.9602/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926515149 CMS
Sunovion Pharmaceuticals Inc. $19.5202/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920991425 CMS
Acorda Therapeutics, Inc $9.9902/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920333145 CMS
MDD US Operations, LLC $19.0202/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951620509 CMS
UCB, Inc. $18.6902/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908003809 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $38,559.74 291
PY2020 $10,708.75 251
PY2021 $14,078.06 355
PY2022 $29,244.06 279
PY2023 $26,387.85 253
PY2024 $5,809.35 250
PY2025 $8,313.58 240

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $185,331.50 34
PY2024 Principal investigator $182,774.45 36
PY2023 Recipient $4,774.99 1
PY2023 Principal investigator $263,413.84 103
PY2022 Principal investigator $184,870.52 51
PY2021 Principal investigator $110,461.25 31
PY2020 Principal investigator $29,895.12 7
PY2019 Recipient $6,548.80 4
PY2019 Principal investigator $78,176.03 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $4,732.28 10/27/2025 Non-covered Recipient Entity
Parkinsons And Movement Disorder Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184289434
Principal investigator 1 Ipsen Innovation $4,247.60 10/27/2025 Non-covered Recipient Entity
Parkinsons And Movement Disorder Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184289436
Principal investigator 1 Ipsen Innovation $5,409.88 10/27/2025 Non-covered Recipient Entity
Parkinsons And Movement Disorder Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184289438
Principal investigator 1 H. Lundbeck A S $3,702.60 09/04/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251774261
Principal investigator 1 H. Lundbeck A S $1,851.30 08/26/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251773958
Principal investigator 1 Ipsen Innovation $15,000.00 08/06/2025 Non-covered Recipient Entity
Parkinsons And Movement Disorder Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184289430
Principal investigator 1 Ipsen Innovation $2,500.00 08/04/2025 Non-covered Recipient Entity
Parkinsons And Movement Disorder Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184289432
Principal investigator 1 H. Lundbeck A S $1,851.30 07/31/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251772902
Principal investigator 1 Ipsen Innovation $43.50 07/21/2025 Non-covered Recipient Entity
The Truong Neuroscience Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184289254
Principal investigator 1 H. Lundbeck A S $2,158.15 07/17/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251772394
Principal investigator 1 H. Lundbeck A S $2,158.15 07/10/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251772064
Principal investigator 1 H. Lundbeck A S $1,851.30 06/24/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251771491
Principal investigator 1 ABBVIE INC. $485.00 06/05/2025 Non-covered Recipient Entity
PARKINSONS AND MOVEMENT DISORDER INSTITUTE
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202490577
Principal investigator 1 H. Lundbeck A S $1,851.30 06/05/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251770688
Principal investigator 1 H. Lundbeck A S $1,851.30 05/27/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251770645
Principal investigator 1 H. Lundbeck A S $1,851.30 05/22/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251770580
Principal investigator 1 H. Lundbeck A S $5,438.30 04/15/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251769665
Principal investigator 1 UCB SA $9,433.77 04/14/2025 Non-covered Recipient Entity
PARKINSONS DIS AND MOVEMENT DISORDER INSTITUTE INC
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246659416
Principal investigator 1 Ipsen Innovation $3,733.13 04/04/2025 Non-covered Recipient Entity
Parkinsons And Movement Disorder Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184289440
Principal investigator 1 Sage Therapeutics, LLC $27,634.00 04/04/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
Study to Evaluate SAGE-324 in Participants With Essential Tremors No dispute reported 06/30/2026 1206580885
Principal investigator 1 H. Lundbeck A S $2,160.00 03/14/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251768757
Principal investigator 1 H. Lundbeck A S $648.00 03/14/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251768760
Principal investigator 1 H. Lundbeck A S $3,702.60 03/11/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251768626
Principal investigator 1 ABBVIE INC. $260.34 02/27/2025 Non-covered Recipient Entity
PARKINSONS AND MOVEMENT DISORDER INSTITUTE
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) No dispute reported 06/30/2026 1202455005
Principal investigator 1 ABBVIE INC. $290.00 02/06/2025 Non-covered Recipient Entity
PARKINSONS AND MOVEMENT DISORDER INSTITUTE
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) No dispute reported 06/30/2026 1202450070
Principal investigator 1 H. Lundbeck A S $2,160.00 02/06/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251767153
Principal investigator 1 H. Lundbeck A S $648.00 02/06/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251767157
Principal investigator 1 H. Lundbeck A S $3,702.60 02/05/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251767027
Principal investigator 1 H. Lundbeck A S $2,160.00 01/17/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251766566
Principal investigator 1 H. Lundbeck A S $648.00 01/17/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251766569
Principal investigator 1 H. Lundbeck A S $15,765.80 01/15/2025 Non-covered Recipient Entity
THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251766535
Principal investigator 1 UCB SA $9,690.00 01/15/2025 Non-covered Recipient Entity
PARKINSON'S & MOVEMENT DISORDERS INSTITUTE
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246657482
Principal investigator 1 UCB SA $1,200.00 01/09/2025 Non-covered Recipient Entity
PARKINSONS DIS AND MOVEMENT DISORDER INSTITUTE INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE No dispute reported 06/30/2026 1246658540
Principal investigator 1 UCB SA $44,512.00 01/07/2025 Non-covered Recipient Entity
PARKINSONS DIS AND MOVEMENT DISORDER INSTITUTE INC
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246658762